SCHEMBL7129773

SCHEMBL7129773

O=C(NCc1cc(F)cc(F)c1)c1cccc2c1C(S(=O)(=O)c1ccccc1)CS2(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
AURKA O14965 1/20 0.40
HTT P42858 1/20 0.40
USP2 O75604 1/20 0.39
TLR9 Q9NR96 1/20 0.39
CRHBP P24387 2/20 0.39
CRHR2 Q13324 2/20 0.39
CXCR4 P61073 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
POLB P06746 2/20 0.37
MAPK1 P28482 1/20 0.37
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
LMNA P02545 1/20 0.36
RAB9A P51151 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7132386 0.93 USP2 (0.46) HSD17B10ALDH1A1GAAHTTUSP2
SCHEMBL7129768 0.90 HSD17B10 (0.40) HSD17B10ALDH1A1GAAAURKAHTT
SCHEMBL7124773 0.90 GAA (0.47) HSD17B10ALDH1A1GAAHTTKMT2A
SCHEMBL7124893 0.86 RAB9A (0.46) HSD17B10ALDH1A1GAAHTTUSP2
SCHEMBL7128198 0.86 POLB (0.41) USP2TLR9CXCR4CYP1A2CYP2C19
SCHEMBL7132519 0.86 ALDH1A1 (0.49) HSD17B10ALDH1A1GAAHTTKMT2A
SCHEMBL7128745 0.85 POLB (0.48) ALDH1A1KMT2APOLBLMNA
SCHEMBL7128579 0.85 MAPK1 (0.46) HSD17B10ALDH1A1GAAHTTCYP2C19
SCHEMBL7132804 0.84 APEX1 (0.45) HSD17B10ALDH1A1GAAKMT2APOLB
SCHEMBL7132384 0.84 USP2 (0.44) HSD17B10ALDH1A1GAAHTTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed
US-6555555-B1 Inhibitors of interleukin-6 and/or interleukin-12; for example 4,5-dimethyl-1,1-dioxidebenzo(b)thiophene; treating various inflammatory diseases, autoimmune diseases, cancer, osteoporosis ONO PHARMACEUTICAL CO., LTD. (JP) 2003-04-29 US disclosed
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US disclosed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO HSD17B10 2541/4885ALDH1A1 3159/4885GAA 3518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.